title: XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer.
abstract: The aim of this study was to compare the efficacy, safety and survival rate of a treatment regimen comprising capecitabine plus irinotecan (XELIRI) to those of a standard regimen comprising leucovorin, fluorouracil and irinotecan (FOLFIRI), to determine the correlation among the inherited genetic variations inUGT1A1,UGT1A7andUGT1A9. A total of 84 consecutive patients with histologically confirmed metastatic colorectal cancer (mCRC) were included in the study. All patients were treated with FOLFIRI or XELIRI. The median progression-free survival time was 4.4 months for FOLFIRI and 5.7 months for XELIRI (hazard ratio=1.35; 95% confidence interval, 0.83-2.21; P=0.22). When compared with FOLFIRI (6.34%), XELIRI was associated with lower rates of severe toxicity (3.29) (P=0.026) and similar disease control rates (69.57% for FOLFIRI and 61.11% for XELIRI; P=0.49). In total, 17 single nucleotide polymorphisms were identified, five of which revealed an association with grade 3/4 neutropenia, includingUGT1A7*4; however,UGT1A1*28andUGT1A1*6, which have been previously reported, were not significant. Additionally, H2 haplotypes, which includeUGT1A9*22, and H5 and H7 haplotypes, which includeUGT1A7*2,UGT1A7*3andUGT1A7*4, were associated with a higher risk of severe neutropenia. In conclusion, XELIRI is an effective treatment regimen with acceptable response rates and tolerability for mCRC patients as a second-line treatment. Furthermore, inherited genetic variations inUGT1A1,UGT1A7andUGT1A9are associated with grade 3/4 neutropenia.
authors.affiliation: Department of Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing 100021, P.R. China ; Department of Oncology, Beijing Chaoyang San Huan Cancer Hospital, Beijing 100122, P.R. China.
authors.forename: Chengxu
authors.initials: C
authors.lastname: Cui
authors.affiliation: CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, P.R. China.
authors.forename: Chang
authors.initials: C
authors.lastname: Shu
authors.affiliation: CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, P.R. China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Oncology, Beijing Chaoyang San Huan Cancer Hospital, Beijing 100122, P.R. China.
authors.forename: Junbao
authors.initials: J
authors.lastname: Liu
authors.affiliation: Department of Oncology, Beijing Chaoyang San Huan Cancer Hospital, Beijing 100122, P.R. China.
authors.forename: Shuping
authors.initials: S
authors.lastname: Shi
authors.affiliation: Department of Oncology, Beijing Chaoyang San Huan Cancer Hospital, Beijing 100122, P.R. China.
authors.forename: Zhujun
authors.initials: Z
authors.lastname: Shao
authors.affiliation: Department of Oncology, Beijing Chaoyang San Huan Cancer Hospital, Beijing 100122, P.R. China.
authors.forename: Nan
authors.initials: N
authors.lastname: Wang
authors.affiliation: Department of Oncology, Beijing Chaoyang San Huan Cancer Hospital, Beijing 100122, P.R. China.
authors.forename: Ting
authors.initials: T
authors.lastname: Yang
authors.affiliation: CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing 100101, P.R. China.
authors.forename: Songnian
authors.initials: S
authors.lastname: Hu
keywords: FOLFIRI; UGT1A; XELIRI; haplotype; polymorphism